At Investor Conferences


Picture [iito] Back into Ad 650x80px
Financing › Details

Inscripta–SEVERAL: investment, 201912 financing round Series D $125m led by Paladin Capital Group


Period Period 2019-12-10
  Predecessor Inscripta–SEVERAL: investment, 201904 financing round Series C 2nd expansion $20m from existing investors bringing total Series C to $105.5m
Organisations Money taker Inscripta Inc.
  Group Inscripta (Group)
  Money source SEVERAL
Product Product  venture capital

Inscripta, Inc.. (12/10/19). "Press Release: Inscripta Raises $125m in Series D Financing to Accelerate Commercialization of Revolutionary Digital Genome Engineering Platform". Boulder, CO.

New Funding Brings Total Amount Raised by the Company to $259.5 Million

Inscripta, Inc., today announced the company has raised $125 million in a Series D financing with support from the company’s existing investors and new investors JS Capital Management LLC and Oak HC/FT. Paladin Capital Group led the round, bringing the total amount raised by the company to $259.5 million. The new funds will be used to accelerate applications expansion and commercialization of the company’s revolutionary Onyx™ Digital Genome Engineering platform.

The Onyx platform is the world’s first fully automated benchtop instrument for genome-scale engineering. Consisting of an instrument, consumables, software, and assays, it enables scientists to create libraries of millions of precisely engineered single cells in one experiment through a fully automated workflow. The new platform offers immediate and significant benefits that will give scientists in genome discovery, healthcare, bio-industrial materials development and manufacturing, and sustainability the power to design, engineer, evaluate, and track results of genome engineering experiments in their own labs.

“We have been extremely impressed with the Inscripta team’s passion, focus, and relentless execution, which culminated in the successful launch of the Onyx Digital Genome Engineering platform,” said Paul Conley, PhD, Managing Director & Venture Studio Director at Paladin Capital Group. ?“We are thrilled to lead this funding round and believe Inscripta’s technology will be essential for enabling biology to become the driving force of our economy.”

“The overwhelming interest we received with the recent launch of our Onyx platform along with this significant funding offer tremendous validation of our novel approach to genome engineering and its power to unlock the full potential of the emerging bioeconomy,” said Kevin Ness, PhD, CEO of Inscripta. ?“We are excited to see that by overcoming the limitations of existing CRISPR-based gene editing, our digital genome engineering tools are already having a significant impact by enabling researchers to design experiments that were previously impossible. The new funding provides us with the resources to ramp up faster to meet the anticipated high demand for our platform.”

About Inscripta

Inscripta is developing the world’s first benchtop platform for scalable digital genome engineering. The company’s advanced CRISPR-based platform, consisting of an instrument, consumables, software, and assays, offers a fully automated workflow that enables massively parallel, trackable editing of single cells at an unprecedented scale. Inscripta’s goal is to empower scientists whose gene editing research is stifled by current technical and licensing limitations. By providing this unique platform and engaging in collaborative business practices, such as making its MAD7™ CRISPR nuclease free for research and development purposes, the company enables scientists to realize a new era of biological discovery. Headquartered in Boulder, Colo., with offices in Pleasanton, Calif., and San Diego, Inscripta is backed by leading investors including Venrock, Foresite, Paladin Capital Group, Mérieux Développement, NanoDimension, MLS Capital, JS Capital Management LLC, and Oak HC/FT. For more information, visit

Media Contact:

Nicole Litchfield
Bioscribe, Inc.

Record changed: 2020-01-06


Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for Inscripta (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture EBD Group BioPharm America 2020 Digital Event BEU2020 650x81

» top